One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Incorporating VEGF Blockade Into a Shifting Treatment Paradigm for Mucosal Melanoma
Alexander N. Shoushtari , MD1
doi : 10.1200/JCO.20.03523
Journal of Clinical Oncology 39, no. 8 (March 10, 2021) 867-869.
Consolidation Therapy for Acute Myeloid Leukemia: Defining a Benchmark
Selina M. Luger, MD1
doi : 10.1200/JCO.20.03142
Journal of Clinical Oncology 39, no. 8 (March 10, 2021) 870-875.
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in the Journal of Clinical Oncology, to patients seen in their own clinical practice.
Presumed Consent With Opt-Out: An Ethical Consent Approach to Automatically Refer Patients With Cancer to Tobacco Treatment Services
Joshua W. Ohde , BS1; Zubin Master , PhD2; Jon C. Tilburt, MD3; and David O. Warner , MD4
doi : 10.1200/JCO.20.03180
Journal of Clinical Oncology 39, no. 8 (March 10, 2021) 876-880.
Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma
Xieqiao Yan, MD1; Xinan Sheng, MD1; Zhihong Chi, MD1; Lu Si, MD1; Chuanliang Cui, MD1; Yan Kong, PhD1; Bixia Tang, MD1; Lili Mao, MD1; Xuan Wang, MD1; Bin Lian, MD1; Siming Li, MD1; Xue Bai, MD1; Li Zhou, MD1; Jie Dai, PhD1; Hong Yao, MD2; and Jun Guo, MD, PhD1
doi : 10.1200/JCO.20.00902
Journal of Clinical Oncology 39, no. 8 (March 10, 2021) 881-889.
Mucosal melanoma (MM) is a highly vascularized tumor with an extremely poor prognosis. In this randomized, open-label, phase II study, we characterized the efficacy and safety of bevacizumab in combination with carboplatin plus paclitaxel (CPB) in patients with previously untreated advanced MM.
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses
Alan K. Burnett, MD1; Nigel H. Russell , MD2; Robert K. Hills, DPhil3; Stephen Knapper , DM4; Sylvie Freeman , PhD5; Brian Huntly , PhD6; Richard E. Clark , MD7; Ian F. Thomas, MSc8; Lars Kjeldsen, MD, PhD9; Mary Frances McMullin , MD10; Mark Drummond, PhD11; Jonathan Kell , MD12; and Ruth Spearing , MD13
doi : 10.1200/JCO.20.01170
Journal of Clinical Oncology 39, no. 8 (March 10, 2021) 890-901.
The optimum number of treatment courses for younger patients with acute myeloid leukemia (AML) is uncertain. The United Kingdom National Cancer Research Institute AML17 trial randomly assigned patients who were not high risk to a total of three versus four courses.
Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Ellen K. Chang , MD1; Dayana Chanson , MPH2; Jennifer Berano Teh , MD2; Aleksi Iukuridze , BA2; Kelly Peng, BA2; Stephen J. Forman, MD3; Ryotaro Nakamura, MD3; F. Lennie Wong , PhD2; LiYing Cai, MD4; and Saro H. Armenian , DO, MPH2
doi : 10.1200/JCO.20.02401
Journal of Clinical Oncology 39, no. 8 (March 10, 2021) 902-910.
To examine the incidence and risk factors for de novo atrial fibrillation (AF) after allogeneic hematopoietic cell transplantation (HCT) and to describe the impact of AF on HCT-related outcomes.
Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer
Martin R. Weiser, MD1; Meier Hsu, MS2; Philip S. Bauer, MD3; William C. Chapman Jr, MD3; Iv?n A. Gonz?lez, MD4; Deyali Chatterjee, MD4; Deepak Lingam, MD4; Matthew G. Mutch, MD3; Ajaratu Keshinro, MD1; Jinru Shia, MD5; Efsevia Vakiani, MD5; Tsuyoshi Konishi, MD1,6; Yoshifumi Shimada, MD1,7; Zsofia Stadler, MD8; Neil H. Segal, MD, PhD8; Andrea Cercek, MD8; Leonard Saltz, MD8; Rona Yaeger, MD8; Anna Varghese, MD8; Maria Widmar, MD, MPH1; Iris H. Wei, MD1; Emmanouil P. Pappou, MD, PhD1; J. Joshua Smith, MD, PhD1; Garrett Nash, MD, MPH1; Philip Paty, MD1; Julio Garcia-Aguilar, MD, PhD1; and Mithat Gonen, PhD2
doi : 10.1200/JCO.20.02553
Journal of Clinical Oncology 39, no. 8 (March 10, 2021) 911-919.
Clinical calculators and nomograms have been endorsed by the American Joint Committee on Cancer (AJCC), as they provide the most individualized and accurate estimate of patient outcome. Using molecular and clinicopathologic variables, a third-generation clinical calculator was built to predict recurrence following resection of stage I-III colon cancer.
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial
Stephan Kadauke, MD, PhD1; Regina M. Myers, MD2,3; Yimei Li, PhD4; Richard Aplenc, MD, PhD2,3; Diane Baniewicz, CRNP2; David M. Barrett, MD, PhD2,3; Allison Barz Leahy, MD2,3; Colleen Callahan, CRNP2; Joseph G. Dolan, MD2,3; Julie C. Fitzgerald, MD, PhD5; Whitney Gladney, PhD6; Simon F. Lacey, PhD7; Hongyan Liu, PhD4; Shannon L. Maude, MD, PhD2,3; Regina McGuire, BA2; Laura S. Motley, RN2; David T. Teachey, MD2,3; Gerald B. Wertheim, MD, PhD1; Lisa Wray, MD2,3; Amanda M. DiNofia, MD2,3; and Stephan A. Grupp, MD, PhD1,2,3
doi : 10.1200/JCO.20.02477
Journal of Clinical Oncology 39, no. 8 (March 10, 2021) 920-930.
To prospectively evaluate the effectiveness of risk-adapted preemptive tocilizumab (PT) administration in preventing severe cytokine release syndrome (CRS) after CTL019, a CD19 chimeric antigen receptor T-cell therapy.
Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline
Megan E. Daly, MD1; Nofisat Ismaila , MD2; Roy H. Decker , MD, PhD3; Kristin Higgins, MD4; Dawn Owen, MD, PhD5; Ashish Saxena, MD, PhD6; Gregg E. Franklin, MD, PhD7; Dusty Donaldson, MA8; and Bryan J. Schneider, MD9
doi : 10.1200/JCO.20.03364
Journal of Clinical Oncology 39, no. 8 (March 10, 2021) 931-939.
The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on radiation therapy (RT) for small-cell lung cancer (SCLC). Because of the relevance of this topic to ASCO membership, ASCO reviewed the guideline, applying a set of procedures and policies used to critically examine guidelines developed by other organizations.
Beyond a Child's Question: Physicians and the Existential Unknown in End-of-Life Care
Alan B. Astrow , MD1
doi : 10.1200/JCO.20.02728
Journal of Clinical Oncology 39, no. 8 (March 10, 2021) 940-942.
Considerations on the Role of Pembrolizumab Adjuvant Therapy in AJCC-8 Stage IIIA Melanoma
Elif Hindié , MD, PhD
doi : 10.1200/JCO.20.03213
Journal of Clinical Oncology 39, no. 8 (March 10, 2021) 943-944.
Reply to E. Hindié
Alexander M. M. Eggermont , MD, PhD, Christian U. Blank, MD, PhD, Mario Mandala, MD, Georgina V. Long, BSc, MBBS, Victoria G. Atkinson, MBBS, Stéphane Dalle, MD, PhD, Andrew M. Haydon , MBBS, PhD, Andrey Meshcheryakov , MD, PhD, Adnan Khattak, MD, Matteo S. Carlino, BMedSc, MBBS, Shahneen Sandhu, MD, James Larkin , PhD, Susana Puig , MD, PhD, Paolo A. Ascierto , MD, Piotr Rutkowski, MD, PhD, Dirk Schadendorf , MD, PhD, Rutger Koornstra, MD, PhD, Leonel Hernandez-Aya, MD, Anna Maria Di Giacomo, MD, Alfonsus J. M. van den Eertwegh, MD, PhD, Jean-Jacques Grob , MD, Ralf Gutzmer , MD, Rahima Jamal, MD, BSc, Paul C. Lorigan , MD, Alexander C. J. van Akkooi, MD, PhD, Clemens Krepler, MD, Nageatte Ibrahim , MD, Sandrine Marreaud, MD, Michal Kicinski, PhD, Stefan Suciu , PhD, and Caroline Robert , MD, PhD
doi : 10.1200/JCO.20.03463
Journal of Clinical Oncology 39, no. 8 (March 10, 2021) 944-946.
